The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype | Zendy

Antonio RiveroJuárez | Zendy; Luís F. LópezCortés | Zendy; Ángela Camacho | Zendy; Antonio Carúz | Zendy; Almudena Torres-Cornejo | Zendy; Loreto MartinezDueñas | Zendy; Rosa Ruiz-Valderas | Zendy; José Miguel Cisneros | Zendy; Alicia GutiérrezValencia | Zendy; Antonio Rivero | Zendy

Open Access

The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype

Author(s) -

Antonio RiveroJuárez,

Luís F. LópezCortés,

Ángela Camacho,

Antonio Carúz,

Almudena Torres-Cornejo,

Loreto MartinezDueñas,

Rosa Ruiz-Valderas,

José Miguel Cisneros,

Alicia GutiérrezValencia,

Antonio Rivero

Publication year - 2013

Publication title -

aids

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.195

H-Index - 216

eISSN - 1473-5571

pISSN - 0269-9370

DOI - 10.1097/qad.0b013e328360ea1e

Subject(s) - ribavirin , hepatitis c virus , medicine , pegylated interferon , hepatitis c , virology , viral load , gastroenterology , hepacivirus , genotype , alpha interferon , virus , immunology , interferon , biology , biochemistry , gene

To evaluate the IL28B effect on hepatitis C virus (HCV) decline during first weeks of treatment according to HCV-1 subtypes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research